Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid for hepatorenal polycystic diseases
2024-513644-28-00Phase 2Authorised
- Sponsor
- Biogipuzkoa Health Research Institute
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ursodeoxycholic acid in autosomal recessive polycystic kidney disease (ARPKD), Polycystic liver disease (PLD) and polycystic kidney disease (PKD) (2 arms), sponsored by Biogipuzkoa Health Research Institute. Planned start Mar 2026; status: authorised.
02
Drugs
ursodeoxycholic acid
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)Polycystic liver disease (PLD)polycystic kidney disease (PKD)
Beyond the preview
Go deeper on 2024-513644-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513644-28-00.